Notable Labs, Ltd. (NTBL)
| Market Cap | 3.86M |
| Revenue (ttm) | 313,000 |
| Net Income (ttm) | -10.54M |
| Shares Out | 9.66M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,032 |
| Open | 0.380 |
| Previous Close | 0.394 |
| Day's Range | 0.380 - 0.400 |
| 52-Week Range | 0.380 - 6.760 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 5.00 (+1,150.0%) |
| Earnings Date | Nov 12, 2024 |
About NTBL
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company’s pipeline includes... [Read more]
Financial Performance
In 2023, Notable Labs's revenue was $310,000, an increase of 3775.00% compared to the previous year's $8,000. Losses were -$11.26 million, -21.82% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for NTBL stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 1,150.00% from the latest price.
News
Notable Labs to Present Data on September 4th at SOHO 2024
Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE)...
Notable Labs Announces CEO Transition
Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOB...
Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study
Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment Phase 2 dosing plan, agreed with FDA, paves the way to initiate patient enrollment
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer ...
Notable Labs Reports 2023 Financial Results and Provides a Business Update
FOSTER CITY, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies iden...
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer the...
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform
FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer the...
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer t...
Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
FOSTER CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer th...
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
- PPMP Accurately Predicted Patient Outcomes in Fosciclopirox Phase 2a Leukemia Trial - - Predictive Results Further Advance PPMP and Corroborate Outcomes from 4 PPMP Validation Trials - - Furthers Op...
Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
Funds will help advance MDS Education, Advocacy and Research SAN DIEGO , Dec. 13, 2023 /PRNewswire/ -- Notable Labs, Ltd. ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company deve...
Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant
Funds will help advance MDS Education, Advocacy and Research SAN DIEGO , Dec. 11, 2023 /PRNewswire/ -- Notable Labs, ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company developin...
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer...
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable La...
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML
– Article Published in November 9th Issue of ASCO's Journal of Clinical Oncology Precision Oncology (JCO PO) – – Results highlight PPMP as a tool for identifying most promising drug combinations for p...
Notable Labs Closes Merger Transaction With VBL Therapeutics
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved...
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Sh...
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI'IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEW...
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vascular Bioge...
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL's S-4 registration statement being declared effective and shareholder approval
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals Recently filed S-4 registration...
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
MODIIN, Israel and NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), today announced financial results for the fiscal year ended December 31, 2022, and provided a cor...
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in Mod...
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
REHOVOT, Israel--(BUSINESS WIRE)-- #COP26--Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, today announced that it has acquired a manufacturing facility ...